Limits...
Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer

View Article: PubMed Central - PubMed

ABSTRACT

Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.

A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science. The hazard ratios (HRs) and its 95% confidence intervals (CIs) for overall survival (OS), progression-free survival, or recurrence-free survival were extracted and pooled using fix-effects model or random-effects model.

A total of 14 studies that met our criterion were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was not significantly associated with the poor OS (HR = 1.45; 95% CI 0.77–2.71; P = 0.248) or recurrence-free survival (HR = 1.34; 95% CI 0.89–2.02; P = 0.155) of patients with localized PCa. Although elevated NLR predicted poorer OS (HR = 1.57; 95% CI 1.41–1.74; P < 0.001) and progression-free survival (HR = 1.97; 95% CI 1.28–3.04; P = 0.002) of patients with metastatic castration resistant prostate cancer (mCRPC).

Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment.

No MeSH data available.


Related in: MedlinePlus

Forest plot of studies evaluating the association between neutrophil-to-lymphocyte ratio and overall survival in prostate cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4998274&req=5

Figure 2: Forest plot of studies evaluating the association between neutrophil-to-lymphocyte ratio and overall survival in prostate cancer.

Mentions: Only 2 studies reported the HR and 95% CI from OS analysis in patients with localized PCa, with significant heterogeneity (I2 = 76.5%, P = 0.039). The pooled result showed that an elevated NLR was not significantly associated with the OS of localized PCa (HR = 1.45; 95% CI 0.77–2.71; P = 0.248; Figure 2).


Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Prostate Cancer
Forest plot of studies evaluating the association between neutrophil-to-lymphocyte ratio and overall survival in prostate cancer.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4998274&req=5

Figure 2: Forest plot of studies evaluating the association between neutrophil-to-lymphocyte ratio and overall survival in prostate cancer.
Mentions: Only 2 studies reported the HR and 95% CI from OS analysis in patients with localized PCa, with significant heterogeneity (I2 = 76.5%, P = 0.039). The pooled result showed that an elevated NLR was not significantly associated with the OS of localized PCa (HR = 1.45; 95% CI 0.77–2.71; P = 0.248; Figure 2).

View Article: PubMed Central - PubMed

ABSTRACT

Inflammation is increasingly reported to be associated with the prognosis of patients with cancers. And the prognostic role of neutrophil-to-lymphocyte ratio (NLR) in patients with prostate cancer (PCa) remains inconsistent. Therefore, we conducted this systematic review and meta-analysis to obtain a more reliable assessment of prognostic significance of NLR in PCa.

A comprehensive literature research regarding the association of NLR and prognosis of PCa was performed through PubMed, Embase, Cochrane Central, and Web of Science. The hazard ratios (HRs) and its 95% confidence intervals (CIs) for overall survival (OS), progression-free survival, or recurrence-free survival were extracted and pooled using fix-effects model or random-effects model.

A total of 14 studies that met our criterion were included in this meta-analysis. Our pooled results demonstrated that elevated NLR was not significantly associated with the poor OS (HR = 1.45; 95% CI 0.77–2.71; P = 0.248) or recurrence-free survival (HR = 1.34; 95% CI 0.89–2.02; P = 0.155) of patients with localized PCa. Although elevated NLR predicted poorer OS (HR = 1.57; 95% CI 1.41–1.74; P < 0.001) and progression-free survival (HR = 1.97; 95% CI 1.28–3.04; P = 0.002) of patients with metastatic castration resistant prostate cancer (mCRPC).

Elevated NLR is a strong indicator of poorer prognosis of patients with mCRPC, whereas the NLR is not significantly associated with prognosis of patients with localized PCa. Therefore, NLR could be used in patients with mCRPC for risk stratification and decision making of individual treatment.

No MeSH data available.


Related in: MedlinePlus